E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028228 |
E.1.2 | Term | Multiple myeloma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Compare the ORR between once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an IMiD |
|
E.2.2 | Secondary objectives of the trial |
Progression-free survival (PFS)
Overall survival (OS)
Safety and tolerability
Pharmacokinetics (PK) of carfilzomib using sparse sampling |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
INTENSIVE PHARMACOKINETICS/PHARMACODYNAMICS SUBSTUDY
&
SPARSE PHARMACOKINETIC SAMPLING
|
|
E.3 | Principal inclusion criteria |
1. Age ≥ 18 years
2. Able to provide written informed consent in accordance with federal, local, and institutional
guidelines
3. Relapsed multiple myeloma
4. Refractory multiple myeloma defined as meeting 1 or more of the following:
a. Nonresponsive to most recent therapy (stable disease only or PD while on treatment), or
b. Disease progression within 60 days of discontinuation from most recent therapy
5. At least 2 but no more than 3 prior therapies for multiple myeloma
6. Prior exposure to an immunomodulatory agent (IMiD)
7. Prior exposure to a proteasome inhibitor (PI)
8. Documented response of at least partial response (PR) to 1 line of prior therapy
9. Measurable disease with at least 1 of the following assessed within the 21 days prior to
randomization:
a. Serum M-protein ≥ 0.5 g/dL
b. Urine M-protein ≥ 200 mg/24 hours
c. In subjects without detectable serum or urine M-protein, serum free light chain (SFLC) ≥ 100
mg/L (involved light chain) and an abnormal serum kappa lambda ratio
10. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
11. Left ventricular ejection fraction (LVEF) ≥ 40% within the 21 days prior to randomization
12. Adequate organ and bone marrow function within the 21 days prior to randomization defined by:
a. Bilirubin < 1.5 times the upper limit of normal (ULN)
b. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
< 3 times the ULN
c. Absolute neutrophil count (ANC) ≥ 1000/mm3 (screening ANC should be independent of growth
factor support for ≥ 1 week)
d. Hemoglobin ≥ 8.0 g/dL (Use of erythropoietic stimulating factors and red blood cell [RBC]
transfusion per institutional guidelines is allowed, however the most recent RBC transfusion may
not have been done within 7 days
prior to obtaining screening hemoglobin.)
e. Platelet count ≥ 50,000/mm3 (≥ 30,000/mm3 if myeloma involvement in the bone marrow is > 50%.
Subjects should not have received platelet transfusions for at least 1 week prior to obtaining the
screening platelet count.)
f. Calculated or measured creatinine clearance (CrCl) of ≥ 30 mL/min
Calculation should be based on the Cockcroft and Gault formula:
[(140 – Age) x Mass (kg) / (72 x Creatinine mg/dL)]; multiply result by 0.85 if female
13. Females of childbearing potential (FCBP) must have a confirmed negative serum pregnancy test
within the 21 days prior to randomization (performed at a central laboratory).
14. Females of childbearing potential and male subjects who are sexually active with
FCBP must agree to use effective concomitant method(s) of contraception during
the study and for 30 days following the last study drug treatment administration.
|
|
E.4 | Principal exclusion criteria |
1. Waldenström macroglobulinemia
2. Multiple myeloma of Immunoglobin M (IgM) subtype
3. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin
changes)
4. Plasma cell leukemia (> 2.0 × 109/L circulating plasma cells by standard differential)
5. Myelodysplastic syndrome
6. Second malignancy within the past 5 years except:
a. Adequately treated basal cell or squamous cell skin cancer b. Carcinoma in situ of the
cervix
c. Prostate cancer < Gleason score 6 with stable prostate-specific antigen
(PSA) over 12 months
d. Ductal breast carcinoma in situ with full surgical resection (i.e., negative margins)
e. Treated medullary or papillary thyroid cancer
f. Similar condition with an expectation of > 95% five-year disease-free survival
7. History of or current amyloidosis
8. Cytotoxic chemotherapy within the 28 days prior to randomization
9. Immunotherapy within the 21 days prior to randomization
10. Glucocorticoid therapy within the 14 days prior to randomization that exceeds a cumulative
dose of 160 mg of dexamethasone or 1000 mg prednisone
11. Radiation therapy:
a. Focal therapy within the 7 days prior to randomization
b. Extended field therapy within the 21 days prior to randomization
12. Prior treatment with either carfilzomib or oprozomib
13. Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize
carfilzomib)
14. Contraindication to dexamethasone or any of the required concomitant drugs or supportive
treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to
pre-existing pulmonary or cardiac impairment
15. Active congestive heart failure (New York Heart Association [NYHA] Class III or IV, refer to
Appendix F), symptomatic ischemia, conduction abnormalities uncontrolled by conventional
intervention, acute diffuse infiltrative pulmonary disease, pericardial disease, or myocardial
infarction within 6 months prior to enrollment
16. Active infection within the 14 days prior to randomization requiring systemic antibiotics
17. Pleural effusions requiring thoracentesis within the 14 days prior to randomization
18. Ascites requiring paracentesis within the 14 days prior to randomization
19. Ongoing graft-versus-host disease
20. Uncontrolled hypertension or uncontrolled diabetes despite medication
21. Significant neuropathy (≥ Grade 3) within the 14 days prior to randomization
22. Known cirrhosis
23. Known human immunodeficiency virus (HIV) seropositivity, hepatitis C infection,
or hepatitis B infection (subjects with past hepatitis B virus (HBV) infection or
resolved HBV infection defined as having a negative HBsAg test and a positive
antibody to hepatitis B core antigen [anti HBc] antibody test are eligible; subjects
positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain
reaction (PCR) is negative for HCV RNA.)
24. Participation in another interventional study within the 28 days prior to
randomization
25. Major surgery (except kyphoplasty) within the 28 days prior to randomization
26. Female subjects who are pregnant or lactating
27. Any other clinically significant medical disease or social condition that, in the
investigator’s opinion, may interfere with protocol adherence or a subject’s ability
to give informed consent, be compliant with study procedures, or provide accurate
information. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is ORR, which is defined as the proportion of subjects who achieved a
confirmed PR, VGPR, CR, or sCR according to the IMWG-URC |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
* Assessment every 4 weeks to collect lab-data (Blood and Urine) for response assessment bone-marrow biopsy (only once) in case of to confirm CR/sCR or if progression in bone-marrow plasma-cell – percentage suspected. If baseline soft tissue plasmacytoma present, repetition of this imaging if progressive disease suspected clinically or to confirm MR or better in case of given clinical evidence. All these until progressive disease is demonstrated
o After discontinuation of study drug treatment and demonstration of disease progression, survival follow up every 3 months (short questionnaire may be done via telephone-call) until death confirmed
|
|
E.5.2 | Secondary end point(s) |
The secondary endpoints of the study are as follows:
PFS defined as the time in months from randomization to the earlier of disease
progression or death due to any cause.
OS defined as the time in months from randomization to death due to any cause.
Safety and tolerability |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• Interim analysis of PFS is expected to occur at the time of analysis of ORR, approximately 19 months after the first subject is randomized. Final PFS analysis is expected to occur approximately 25 months after the first subject is randomized.
• Interim analysis of OS is expected to occur at the time of analysis of ORR, approximately 19 months after the first subject is randomized. Final OS analysis is expected to occur approximately 25 months after the first subject is randomized.
• Data will be collected till 30 days after the last administration of study treatment.nter information in English and add any other language that is applicable |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 85 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Canada |
Czech Republic |
Denmark |
France |
Germany |
Greece |
Hungary |
Italy |
Japan |
Poland |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the study defined as when the final OS analysis takes place |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 3 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |